ArticleMolecular cell2022
The Mettl3 epitranscriptomic writer amplifies p53 stress responses.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 61 citations in OpenAlex.
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- RNA Modifications as Molecular Regulators of Alveolar Epithelial Injury and Aberrant Repair in Pulmonary Fibrosis.Biomolecules · 2026Review
- RNA methyltransferase 3 drives pancreatic acinar cell carcinoma growth and is a therapeutic target.Signal transduction and targeted therapy · 2026Article
- The Dynamic Alliance of p53 and Metabolism in the Tumor Microenvironment Shapes Tumor Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Review
- METTL3 regulates exocytosis independently of mScience advances · 2026Article
- mRedox biology · 2026Review
- Quercetin Suppresses Uterine Leiomyoma Progression by Modulating METTL3-Mediated MAPK Signaling.International journal of molecular sciences · 2026Article
- Dynamic modulation of N6-methyladenosine by ionizing radiation in human cells.Biochemistry and biophysics reports · 2026Article
- p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.Cancer discovery · 2026Article
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- RNA modification systems as therapeutic targets.Nature reviews. Drug discovery · 2026Review
- Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The crosstalk of mTrends in biochemical sciences · 2025Review
- mCell · 2025Article
- YTHDF1 promotes p53 translation and induces ferroptosis during acute cerebral ischemia/reperfusion through mCell biology and toxicology · 2025Article
- The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression.The FEBS journal · 2025Article
- VIRMA-mediated mScience advances · 2025Article
- Article
- hnRNPC Functions with HuR to Regulate Alternative Splicing in an m6A-Dependent Manner and is Essential for Meiosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Nitin RajDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mengxiong WangDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jose A SeoaneVall d'Hebron Institute of Oncology (VHIO), Barcelona 08035, Spain.
Richard L ZhaoDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alyssa M KaiserDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Nancie A MoonieBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Janos DemeterBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Anthony M BoutelleDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Craig H KerrDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abigail S MulliganDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Clare MoffattDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Shelya X ZengDepartment of Biochemistry & Molecular Biology, Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Hua LuDepartment of Biochemistry & Molecular Biology, Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Maria BarnaDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Christina CurtisDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Howard Y ChangStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University, Stanford, CA 94304, USA.
Peter K JacksonBaxter Laboratory, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Laura D AttardiDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: attardi@stanford.edu.
Stanford University · USTulane University · USHoward Hughes Medical Institute · USStanford Medicine · USVall d'Hebron Institute of Oncology · ES
Funding
Integrative approaches to elucidate p53 transcriptional networks during carcinogenesisR35CA197591 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI · 2015 to 2026
$11.6MForecasting tumor evolution: can the past reveal the future?DP1CA238296 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N · 2018 to 2022
$5.5MSpecialized Translational Control of Stem Cell Differentiation and Embryonic DevelopmentR01HD086634 · NICHD · STANFORD UNIVERSITY · PI BARNA, MARIA · 2016 to 2025
$5.5MThe Role of Ribosomal Proteins in the P53-MDM2 PathwayR01CA095441 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2002 to 2021
$5.1MRole of the AMPK-MDMX-p53 pathway in cancerR01CA127724 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2007 to 2019
$3.0MIdentifying and Targeting Mechanisms for Membrane Signaling in Human CancerR01CA250534 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACKSON, PETER KENT, SWEET-CORDERO, ERIC ALEJANDRO · 2021 to 2025
$2.7MThe Role of p53-R249S’s GOF in HCC developmentR01CA234605 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI LU, HUA · 2019 to 2023
$1.8MHoward Hughes Medical InstituteNCI NIH HHS DP1 CA238296NCI NIH HHS R01 CA095441NCI NIH HHS R01 CA127724NCI NIH HHS R01 CA234605NCI NIH HHS R01 CA250534NCI NIH HHS R35 CA197591NICHD NIH HHS R01 HD086634
Abstract
The p53 transcription factor drives anti-proliferative gene expression programs in response to diverse stressors, including DNA damage and oncogenic signaling. Here, we seek to uncover new mechanisms through which p53 regulates gene expression using tandem affinity purification/mass spectrometry to identify p53-interacting proteins. This approach identified METTL3, an m
Indexed as
MethyltransferasesTumor Suppressor Protein p53AnimalsCarcinogenesisMiceRNATranscription FactorsMethyltransferasesMettl3 protein, mouseRNATranscription FactorsTumor Suppressor Protein p53DNA damageepitranscriptomicslung cancermass spectrometrymethyltransferase complexMETTL14METTL3N(6)-methyladenosine (m6A) modificationp53tumor suppressor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.